Protocol Ledger

NCT06882057 · Phase II/III · RECRUITING

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Interventional Phase II/III clinical trial protocol NCT06882057 sponsored by Institute of Hematology & Blood Diseases Hospital, China in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-03 Enrollment: 3,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06882057
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06882057
Protocol FieldVerified Registry Value
NCT IdentifierNCT06882057
Consolidated Lead SponsorInstitute of Hematology & Blood Diseases Hospital, China
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,000 participants (ESTIMATED)
Registered Start Date2025-03-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI